ENLV
Enlivex Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.81
+10.92%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.73
From 52W high−95.56%
Volume348410.00
Market cap$14.10M
P/E (TTM)0.0x
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.73
From 52W high
−95.56%
Volume
348410.00
Market cap
$14.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
0.0x
RSI (14)
16.2
MomentumView details →
1D Return
+10.92%
YTD Return
−92.70%
SummaryUpdated Dec 1, 2025
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is an Israeli clinical-stage biotechnology company founded in 2005 and headquartered in Nes Ziona, Israel. The company went public in 2014 and specializes in developing innovative cell-based immunotherapies focused on macrophage reprogramming. Enlivex operates as a pure-play research and development company with no current revenue, dedicating its resources to advancing its lead therapeutic candidate through clinical trials for life-threatening conditions including sepsis and solid tumors.
Similar companies
Latest newsMore news →
Enlivex, a Nasdaq-listed biotech company, is seeking shareholder approval to authorize up to $800 million in financing, potentially increasing share count by up to 951%, with proceeds primarily used to acquire the RAIN crypto token for treasury purposes.51d agoEnlivex announced a private placement of $400,000,000 of ordinary shares to a single institutional investor.54d ago